Advertisement


Peter Schmid, MD, PhD, FRCP, on ER-Positive HER2-Negative Early Breast Cancer: Giredestrant by Menopausal Status

ASCO 2026

Advertisement

Peter Schmid, MD, PhD, FRCP, of Queen Mary University of London, shares more data from the phase III lidERA BC clinical trial. This analysis focused on the efficacy and safety of giredestrant in patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer, looking at both premenopausal and postmenopausal populations (Abstract 502).



Related Videos

Sarcoma

Mark A. Dickson, MD, on Advanced Dedifferentiated Liposarcoma: SARC041 Trial

Mark A. Dickson, MD, of Memorial Sloan Kettering Cancer Center, presents findings from SARC041, a phase III randomized double-blind study of abemaciclib vs placebo in patients with dedifferentiated liposarcoma; patients who received abemaciclib experienced a statistically significant improvement in progression-free survival (Abstract LBA2).

Lung Cancer

Jessica J. Lin, MD, on Neladalkib in Advanced ALK-Positive NSCLC

Jessica J. Lin, MD, Mass General Brigham Cancer Institute, presents data from the ALKOVE-1 study, which is looking at the investigational ALK tyrosine kinase inhibitor (TKI) neladalkib among patients with ALK-positive non–small cell lung cancer (NSCLC); Dr. Lin discusses the first analyses of phase II TKI-pretreated patients and preliminary data in TKI-naive patients (Abstract 8503).

Breast Cancer

Elizabeth McDonald, MD, PhD, on GLP-1 Agonists and Breast Cancer Incidence

Elizabeth McDonald, MD, PhD, of the University of Pennsylvania, discusses results from a retrospective cohort study that showed that the use of GLP-1 treatment was associated with a significantly lower incidence of breast cancer, after accounting for age, race, ethnicity, BMI, breast density, and type 2 diabetes status (Abstract 10506).

Leukemia
Lymphoma

Jennifer A. Woyach, MD, on Pretreated Relapsed or Refractory CLL/SLL: Ongoing ROCKET-CLL Trial

Jennifer A. Woyach, MD, of The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at The Ohio State University, discusses the ongoing, actively recruiting ROCKET-CLL trial, which is a phase III study aiming to compare the efficacy of rocbrutinib vs pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have been pretreated with Bruton tyrosine kinase covalent inhibitors (Abstract TPS7100).

For more information about the trial, visit ClinicalTrials.gov (identifier NCT07342478).

Gynecologic Cancers

Ramez N. Eskander, MD, on Endometrial Cancer: Pembrolizumab Plus Carboplatin/Paclitaxel

Ramez N. Eskander, MD, of UC San Diego Moores Cancer Center, presents an updated overall survival analysis and examination of subsequent therapy in patients with endometrial cancer treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG-GY018 trial (Abstract 5502). 

Advertisement

Advertisement




Advertisement